A clinical and health economic review of a prefilled insulin pen

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2431-2439

  Niskanen, L ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Diabetes; FlexPen; Insulin; Insulin pen

Indexed keywords

BIPHASIC INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN LISPROMIX; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVICE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PEN; MEDICAL APPARATUS, EQUIPMENT AND SUPPLIES; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; REIMBURSEMENT; REVIEW; SYRINGE; VISUAL IMPAIRMENT;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; SYRINGES; TREATMENT OUTCOME;

EID: 77956787461     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.512447     Document Type: Review

References (36)

1. International Diabetes Federation. Diabetes Atlas, 3rd edn. Paris: International Diabetes Federation, 2006
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
5. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl. 2):B21-9
6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167
7. Hunt LM, Valenzueal MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997; 20:292-298
8. Hamilton JG. Needle phobia: a neglected diagnosis. J Family Pract 1995; 41:169-175
9. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone 2006;8(Suppl. 2):S19-26
10. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl. 3):S18-24
11. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ 2002;28:52-6,59-60
12. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-432
13. Pfü tzner A, Asakura T, Sommavilla B, et al. Insulin delivery with FP: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv 2008;5: 915-925
14. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848
15. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004; 26:531-540
16. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther 2005;7:620-626
17. Asakura T, Seino H, Kageyama M, et al. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin 2008;24:1429-1434
18. Hä nel H, Weise A, Sun W, et al. Differences in the dose accuracy of insulin pens. J Diabetes Sci Tech 2008;2:478-481
19. Penfornis A, Horvat K. Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Diabetes Technol Ther 2008; 10:359-362
20. Pfü tzner A, Reimer T, Hohberg C, et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008;24:2545-2549
21. Asakura T. Comparison of the dosing accuracy of two insulin injection devices. J Clin Res 2005;8:33-40
22. Asakura T, Seino H, Kageyama M, et al. Evaluation of injection force of three insulin delivery pens. Expert Opin Pharmacother 2009;10:1389-1393
23. Rissler J, Jørgensen C, Rye Hansen M, et al. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother 2008; 9:2217-2222
24. Sommavilla B, Jørgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 2008;9:2223-2232
25. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007; 27:948-962
26. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294-1305
27. Davis EM, Christensen CM, Nystrom KK, et al. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospi-talization. Am J Health Syst Pharm 2008;65:1347-1357
28. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
29. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999;22:137-140
30. Kesson CM, Bailie GR. Do diabetic patients inject accurate doses of insulin? Diabetes Care 1981;4:333
31. Puxty JA, Hunter DH, Burr WA. Accuracy of insulin injection in elderly patients. BMJ (Clin Res Ed) 1983;287:1762
32. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child 1998;79:59-62
33. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998; 20:486-496
34. Brunton S. Initiating insulin therapy in Type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-256
35. Buch H, Vinding T, La Cour M, et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 2004;111:53-61
36. Sinclair AJ, Conroy SP, Bayer AJ. Impact of diabetes on physical function in older people. Diabetes Care 2008;31:233-235